A chemiluminescent light system in combination with toluidine blue to assess suspicious oral lesions—clinical evaluation and review of the literature
- 344 Downloads
The aim of the study was an evaluation of an acetic acid wash and chemiluminescent light system in combination with toluidine blue in order to detect visual identified, potentially malignant lesions.
Materials and methods
Forty-four patients with 50 oral lesions of primary uncertain visible dignity were included. Next to a clinical examination, a screening with ViziLite® (VL) as well as toluidine blue (TB; together ViziLite® Plus (VLP)) was conducted. Histopathology served as gold standard and sensitivity (SE), specificity (SP), positive as well as negative predictive value (PPV, NPV) was calculated descriptively. Additionally, a PubMed literature search using the key words “ViziLite” and “chemiluminescence oral cancer” was conducted.
Histological diagnosis showed 40 lesions of reactive/inflammatory nature, moderate dysplasia (n = 3) and oral squamous cell carcinoma (OSCC n = 7). All OSCCs and one dysplasia were identified correct via clinical diagnosis (SE 90 %, SP 100 %, PPV 100 %, NPV 97.5 %). VL examination could show all malignancies with low specificity (SE 100 %, SP 30 %, PPV 26 %, NPV 100 %). TB and VLP were positive in all cases of cancer and in one case of inflammation (SE 80 %, SP 97.5 %, PPV 89 %, NPV 95 %). In the review, eight clinical trials with similar results were included.
The adjunct of TB to VL reduces the number of false positives without increasing the rate of false negatives.
Clinical evidence to justify the additional cost of the system for diagnosis of suspicious lesions is weak. However, for the potential role of VLP in detection of lesions not otherwise identified in the visual exam in general dental practice further studies are required.
KeywordsViziLite Chemiluminescence Oral cancer Detection Prevention Review Sensitivity Specificity Visual detection Toluidine blue
Conflicts of interest
Each ViziLite Plus® kit used in this study was provided by the manufacturer at no charge. The authors declare that they have no conflict of interest.
- 2.Sciubba JJ (2000) Oral precancer and cancer: etiology, clinical presentation, diagnosis, and management. Compend Contin Educ Dent 21(892–898):900–902Google Scholar
- 9.Kämmerer PW, Klein MO, Moergel M, Gemmel M, Draenert GF (2013) Local and systemic risk factors influencing the long-term success of angular stable alloplastic reconstruction plates of the mandible. J Craniomaxillofac Surg [Epub ahead of print]Google Scholar
- 18.Brocklehurst P, Kujan O, Glenny AM, Oliver R, Sloan P, Ogden G, Shepherd S (2010) Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev 10:CD004150Google Scholar
- 24.Ujaoney S, Motwani MB, Degwekar S, Wadhwan V, Zade P, Chaudhary M, Hazarey V, Thakre TP, Mamtani M (2012) Evaluation of chemiluminescence, toluidine blue and histopathology for detection of high risk oral precancerous lesions: a cross-sectional study. BMC Clin Pathol 12:6CrossRefPubMedCentralPubMedGoogle Scholar
- 26.Slater LJ (2009) Comment on "analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue" [Epstein JB et al., Oral Oncol 2008;44(6):538–44]. Oral Oncol 45:296Google Scholar
- 35.Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, Graham FJ, Hujoel PP, Kalmar JR, Koch WM, Lambert PM, Lingen MW, Oettmeier BW Jr, Patton LL, Perkins D, Reid BC, Sciubba JJ, Tomar SL, Wyatt AD Jr, Aravamudhan K, Frantsve-Hawley J, Cleveland JL, Meyer DM (2010) Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc 141:509–520CrossRefPubMedGoogle Scholar